Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCH 900222 dose-ranging trial in moderate-to-severe psoriasis
2009-017272-24Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in psoriasis comparing SCH 900222 regimen(s) with Placebo (2 arms). Primary endpoints: PASI 75 response at Week 16, Maintenance of PASI 75 response at Week 52 and 2 more. Started Aug 2010; status: completed.
02
Drugs
tildrakizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2009-017272-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017272-24.